Youth ADHD Peer-facilitated Support Group: Age 16-24

Youth ADHD Surge

ADHD prevalence among young adults has climbed sharply in recent years, driven by factors emerging from the COVID-19 pandemic. Global rates now approach 7% for persistent adult ADHD, up from earlier estimates, with diagnoses in the US rising 61% for those aged 30-44 between 2021 and 2024. In Canada, stimulant prescriptions jumped 157% from 2015 to 2023, reflecting both greater awareness and unmasked symptoms from pandemic disruptions like remote learning and social isolation.

This rise affects millions, particularly those aged 16-24 navigating education, early careers, and personal relationships. Untreated cases lead to tangible harms: higher odds of depression, with 20% of affected youth attempting suicide, and physical health issues like multimorbidity impacting 42% by age 46. Economically, individuals earn less, with lower education and employment rates; one study estimates a 73% drop in social functioning without intervention.

Stakes are concrete and urgent. Life expectancy gaps of 7-9 years stem from modifiable risks like smoking and inadequate support, while ongoing shortages—over 3,000 reported in Canada last year—delay treatment, risking accidents, substance misuse, and job loss. Deadlines loom in policy: DEA quotas increased 25% in late 2025, yet supply lags demand, potentially costing billions in lost productivity.

Non-obvious tensions include gender disparities, with women experiencing steeper diagnosis increases and masking fatigue leading to quiet burnout. Social media fuels self-diagnosis trends, prompting 'diagnosis shopping' among educated young adults, while biohacking alternatives like nootropics emerge amid med shortages. Trade-offs pit quick virtual assessments against thorough evaluations, balancing access with accuracy in a strained system.